M6 Roth- Extracellular Vesicles I + II: Discovery, Biogenesis, Transport and Function

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/15

encourage image

There's no tags or description

Looks like no tags are added yet.

16 Terms

1
New cards

what are extracellular vesicles?

  • cells from all 3 domains produce EVs, by a non-canonical secretory pathway

  • these are vesicles involved in intercellular (not intracellular) cargo transport- for RNAs, proteins, metabolites and even DNA

  • they selectively load cell-specific cargo, protect it from extracellular degradation, and can target delivery to other cells, causing phenotypic changes

  • they are also found in all biofluids (blood, urine, milk, etc)

  • they are very small nanoparticles, about the same size as viruses


there are two major subtypes (but it is difficult to assign these to an EV unless its origin has been observed or we have EV-specific biomarkers):

  • small EVs/exosomes- derived from the endocytic pathway, by inward budding from the plasma membrane

  • large EVs/microvesicles- formed through outward budding of the PM, poorly understood but involves many of the same components (primarily tetraspanin webs)


<ul><li><p>cells from all <strong>3 domains</strong> produce EVs, by a <strong>non-canonical secretory pathway</strong></p></li><li><p>these are vesicles involved in <strong>intercellular </strong>(not intracellular) <strong>cargo transport</strong>- for RNAs, proteins, metabolites and even DNA</p></li><li><p>they selectively load cell-specific cargo, protect it from extracellular degradation, and can target delivery to other cells, causing phenotypic changes</p></li><li><p>they are also found in all biofluids (blood, urine, milk, etc)</p></li><li><p>they are very small <strong>nanoparticles</strong>, about the same size as viruses</p></li></ul><p></p><p>there are <strong>two major subtypes</strong> (but it is difficult to assign these to an EV unless its origin has been observed or we have EV-specific biomarkers):</p><ul><li><p><strong>small EVs/exosomes</strong>- derived from the <strong>endocytic </strong>pathway, by <strong>inward </strong>budding from the plasma membrane</p></li><li><p><strong>large EVs/microvesicles</strong>- formed through <strong>outward </strong>budding of the PM, <strong>poorly understood</strong> but involves many of the <strong>same </strong>components (primarily <strong>tetraspanin </strong>webs)</p></li></ul><p></p>
2
New cards

how are small extracellular vesicles (endosomes) produced?

  • exosomes are derived from the endocytic pathway, by the receptor-mediated inward budding of the plasma membrane

  • inward budding produces an early endosome

  • these endosomes specifically take up cytosolic contents, including proteins, RNAs, DNA + metabolites, into intraluminal vesicles (ILV), to form a multivesicular body (MVB)

  • instead of fusing with lysosomes (for degradation at the vacuole, like the normal endocytic pathway), some MVBs fuse with the plasma membrane to release these extracellular vesicles out of the cell


<ul><li><p>exosomes are derived from the<strong> endocytic pathway</strong>, by the receptor-mediated<strong> inward budding</strong> of the plasma membrane </p></li><li><p>inward budding produces an <strong>early endosome</strong> </p></li><li><p>these endosomes <strong>specifically </strong>take up cytosolic contents, including proteins, RNAs, DNA + metabolites, into <strong>intraluminal vesicles</strong> (ILV), to form a <strong>multivesicular body</strong> (MVB)</p></li><li><p>instead of fusing with lysosomes (for degradation at the vacuole, like the normal endocytic pathway), some <strong>MVBs fuse</strong> with the <strong>plasma membrane</strong> to <strong>release </strong>these extracellular vesicles out of the cell</p></li></ul><p></p>
3
New cards

how were extracellular vesicles discovered?

  • by coincidence, during a study on the clotting factors of blood

  • before this we believed that platelets were the primary blood coagulation factor, however the removal of platelets from plasma still resulted in clotting

  • centrifugation of the plasma (removing EVs), removed the clotting properties of blood- and adding the sediment back restored them

  • in fact, platelets release EVs that induce clotting (rich in phospholipids, ATP and contractile proteins)

  • EVs were finally identified using transmission electron microscopes, but were initially considered as artefacts, or cellular debris


<ul><li><p>by <strong>coincidence</strong>, during a study on the <strong>clotting factors of blood</strong></p></li><li><p>before this we believed that <strong>platelets </strong>were the primary blood coagulation factor, however the <strong>removal </strong>of platelets from plasma <strong>still resulted in clotting</strong></p></li><li><p><strong>centrifugation </strong>of the plasma (removing EVs), <strong>removed </strong>the clotting properties of blood- and <strong>adding </strong>the sediment <strong>back restored </strong>them</p></li><li><p>in fact, <strong>platelets release EVs that induce clotting </strong>(rich in phospholipids, ATP and contractile proteins)</p></li><li><p>EVs were finally identified using transmission electron microscopes, but were initially considered as artefacts, or cellular debris</p></li></ul><p></p>
4
New cards

how do we know EV packaging is selective and functional?

  • we know EV packaging is selective because mast cells EVs take up miRNA + mRNA, but not rRNA (not just generalised uptake of RNA)

  • this RNA is protected against RNAase degradation inside the vesicles

  • if EVs contain miRNAs, this means they could regulate phenotypic changes in a target cell by uptake of the exosomal contents, and miRNA binding to down-regulate target mRNA → cell-cell communication

  • this is exceptionally selective, since specific miRNA complements are exclusively packaged → with known functions in mast cell activity eg. tumorigenesis

  • mRNA cargo has been shown to be taken up by recipient cells, where they get translated- for example in glioblastoma (malignant tumour) cells, to increase angiogenesis (vascular tube formation) → can be used as a diagnostic marker


<ul><li><p>we know EV packaging is selective because <strong>mast cells</strong> EVs take up <strong>miRNA + mRNA</strong>, but <strong>not rRNA</strong> (not just generalised uptake of RNA)</p></li><li><p>this RNA is <strong>protected</strong> against <strong>RNAase degradation</strong> inside the vesicles</p></li><li><p>if EVs contain miRNAs, this means they could regulate<strong> phenotypic changes</strong> in a target cell by <strong>uptake </strong>of the exosomal contents, and miRNA <strong>binding </strong>to <strong>down-regulate </strong>target mRNA → cell-cell communication</p></li><li><p>this is exceptionally <strong>selective</strong>, since <strong>specific miRNA complements </strong>are exclusively packaged → with <strong>known functions </strong>in mast cell activity eg. tumorigenesis</p></li><li><p>mRNA cargo has been shown to be taken up by recipient cells, where they get <strong>translated</strong>- for example in <strong>glioblastoma </strong>(malignant <strong>tumour</strong>) cells, to increase <strong>angiogenesis </strong>(vascular tube formation) → can be used as a diagnostic marker</p></li></ul><p></p>
5
New cards

by what pathways is cargo specifically loaded into small extracellular vesicles (exosomes) during their biogenesis?

multiple pathways can be involved in small EV (exosome) production by intraluminal vesicle formation in multivesicular bodies (there is a lot of overlap between these pathways):

  • ESCRT-dependent pathway- canonical + default

  • syndecan-syntenin-ALIX pathway- non-canonical

  • tetraspanin (TET) pathway- non-canonical, conserved across all domains, this is the biomarker of EVs

  • ceramide pathway- non-canonical


6
New cards

how is cargo specifically loaded into small extracellular vesicles (exosomes) by the ESCRT-dependent pathway?

multiple pathways can be involved in small EV (exosome) production by intraluminal vesicle formation in multivesicular bodies (there is a lot of overlap between these pathways):

  • ESCRT-dependent pathway- canonical + default

    • ESCRT → endosomal sorting complex required for transport

    • ESCRT-0 detects and binds ubiquitinated proteins targeted for vacuole degradation, as well as the EE membrane

    • this sequentially interacts with other ESCRTs (II, I, III) and clathrins to cluster cargo together

    • ESCRT-III defines the curvature and size of the ILV by forming a cargo-sequestering ring/spiral, and VPS4 cuts it off from the EE membrane


<p><strong>multiple pathways </strong>can be involved in <strong>small EV</strong> (exosome) production by intraluminal vesicle formation in multivesicular bodies (there is a lot of <strong>overlap </strong>between these pathways):</p><ul><li><p><strong>ESCRT</strong>-dependent pathway- <strong>canonical + default</strong></p><ul><li><p>ESCRT <strong>→ e</strong>ndosomal <strong>s</strong>orting <strong>c</strong>omplex <strong>r</strong>equired for <strong>t</strong>ransport</p></li><li><p><strong>ESCRT-0</strong> detects and binds <strong>ubiquitinated </strong>proteins targeted for vacuole degradation, as well as the EE membrane</p></li><li><p>this <strong>sequentially</strong> <strong>interacts </strong>with other <strong>ESCRTs (II, I, III) </strong>and <strong>clathrins </strong>to <strong>cluster </strong>cargo together</p></li><li><p><strong>ESCRT-III </strong>defines the curvature and size of the ILV by forming a <strong>cargo-sequestering ring/spiral</strong>, and <strong>VPS4 </strong>cuts it off from the EE membrane</p></li></ul></li></ul><p></p>
7
New cards

how is cargo specifically loaded into small extracellular vesicles (exosomes) by the syndecan-syntenin-ALIX pathway?

multiple pathways can be involved in small EV (exosome) production by intraluminal vesicle formation in multivesicular bodies (there is a lot of overlap between these pathways):

  • syndecan-syntenin-ALIX pathway- non-canonical

    • this pathway occurs independently from the canonical ESCRT biogenesis pathway involving ubiquitin and ESCRT-0, I and II

    • syndecan proteoglycans in the EE membrane act as coreceptors, binding to G-protein-coupled receptors (growth factor receptors) and to syntenins, via their cytosolic domain

    • these syntenins bind to each other and to tetraspanins to cluster, and recruit ESCRT-III components using the ALIX connecting protein

    • this triggers the formation of ILVs


<p><strong>multiple pathways </strong>can be involved in <strong>small EV</strong> (exosome) production by intraluminal vesicle formation in multivesicular bodies (there is a lot of <strong>overlap </strong>between these pathways):</p><ul><li><p><strong>syndecan-syntenin-ALIX </strong>pathway- non-canonical</p><ul><li><p>this pathway occurs <strong>independently </strong>from the canonical ESCRT biogenesis pathway involving ubiquitin and ESCRT-0, I and II</p></li><li><p><strong>syndecan proteoglycans</strong> in the EE membrane act as <strong>coreceptors</strong>, binding to G-protein-coupled receptors (<strong>growth factor receptors</strong>) and to <strong>syntenins</strong>, via their cytosolic domain</p></li><li><p>these syntenins bind to<strong> each other </strong>and to <strong>tetraspanins </strong>to cluster, and recruit <strong>ESCRT-III </strong>components using the <strong>ALIX </strong>connecting protein</p></li><li><p>this triggers the formation of ILVs</p></li></ul></li></ul><p></p>
8
New cards

how is cargo specifically loaded into small extracellular vesicles (exosomes) by the tetraspanin (TET) pathway?

multiple pathways can be involved in small EV (exosome) production by intraluminal vesicle formation in multivesicular bodies (there is a lot of overlap between these pathways):

  • tetraspanin pathway- non-canonical, conserved across all domains, this is the biomarker of EVs

    • this pathway occurs independently from the canonical ESCRT biogenesis pathway

    • tetraspanins contain 4 TM domains across the EE membrane and a large extracellular loop

    • these form tetraspanin webs/nanodomains at the membrane, binding to each other and to various partner proteins


<p><strong>multiple pathways </strong>can be involved in <strong>small EV</strong> (exosome) production by intraluminal vesicle formation in multivesicular bodies (there is a lot of <strong>overlap </strong>between these pathways):</p><ul><li><p><strong>tetraspanin </strong>pathway- non-canonical, conserved across all domains, this is<strong> the biomarker of EVs</strong></p><ul><li><p>this pathway occurs <strong>independently </strong>from the canonical ESCRT biogenesis pathway</p></li><li><p>tetraspanins contain <strong>4 TM domains</strong> across the EE membrane and a <strong>large extracellular loop</strong></p></li><li><p>these form <strong>tetraspanin webs/nanodomains </strong>at the membrane, binding to <strong>each other </strong>and to various <strong>partner proteins </strong></p></li></ul></li></ul><p></p>
9
New cards

how is cargo specifically loaded into small extracellular vesicles (exosomes) by the ceramide pathway?

multiple pathways can be involved in small EV (exosome) production by intraluminal vesicle formation in multivesicular bodies (there is a lot of overlap between these pathways):

  • ceramide pathway- non-canonical

    • ceramides are produced from sphingomyelin lipids in the membrane, by removing a large head group component

    • reducing the size of the head group causes structural negative curvature of the membrane


<p><strong>multiple pathways </strong>can be involved in <strong>small EV</strong> (exosome) production by intraluminal vesicle formation in multivesicular bodies (there is a lot of <strong>overlap </strong>between these pathways):</p><ul><li><p><strong>ceramide </strong>pathway- non-canonical</p><ul><li><p>ceramides are produced from <strong>sphingomyelin lipids </strong>in the membrane, by <strong>removing a large head group component</strong></p></li><li><p>reducing the size of the head group causes structural <strong>negative curvature</strong> of the membrane </p></li></ul></li></ul><p></p>
10
New cards

how are multivesicular bodies transported intracellularly to the plasma membrane?

  • instead of being transported to the lysosome + vacuole for degradation, some MVBs are transported to the plasma membrane to release their intraluminal vesicles as extracellular vesicles

  • MVBs are transported via microtubule motors (dynein + kinesin) to the plasma membrane, mediated by Rab GTPases

  • specific Rabs (7) are involved in direction to the lysosome, and others (27 + 35) are involved in direction + docking to the PM (alongside SNAREs etc), acting as a secretory vesicle


<ul><li><p>instead of being transported to the lysosome + vacuole for degradation, some MVBs are transported to the plasma membrane to release their intraluminal vesicles as extracellular vesicles</p></li><li><p>MVBs are transported via<strong> microtubule motors</strong> (dynein + kinesin) to the plasma membrane, mediated by <strong>Rab GTPases</strong></p></li><li><p>specific Rabs (7) are involved in direction to the <strong>lysosome</strong>, and <strong>others </strong>(27 + 35) are involved in <strong>direction + docking to the PM </strong>(alongside SNAREs etc), acting as a secretory vesicle</p></li></ul><p></p>
11
New cards

what are the mechanisms of extracellular vesicle uptake?

this process is quite poorly understood

  • proteins on the surface of EVs can either trigger uptake by membrane fusion and EV content release, or just direct changes in the target cell by target docking

  • endocytosis of EVs by recipient cells can be mediated by clathrin in the regular endocytic pathway, triggered by receptors on the EV surface (even inter-organismally)

  • phagocytosis and micropinocytosis can also be involved


12
New cards

how are extracellular vesicles involved in RBC iron uptake?

this was the experimental evidence for EVs being involved in secretion by the endocytic pathway

  • reticulocytes are immature red blood cells produced by the bone marrow

  • these have transferrin receptors (TfRs) in their plasma membrane that bind transferrin (Tf) bound to two iron

  • this triggers receptor-mediated endocytosis (using a clathrin coat) into the RBC to form an early endosome containing a membrane iron transporter and a proton pump

  • maturation of the early endosome into the late endosome, producing a more acidic lumen (influx of H+), causes iron to dissociate from Tf and be exported into the cytosol

  • Tf and TfR are recycled back to the plasma membrane and extracellular space

  • during reticulocyte maturation TfR are lost from the PM by internalisation into intraluminal vesicles and export as part of EVs, once the desired iron levels are achieved (30 minutes)


<p>this was the experimental evidence for EVs being involved in secretion by the endocytic pathway</p><ul><li><p><strong>reticulocytes </strong>are <strong>immature red blood cells</strong> produced by the bone marrow</p></li><li><p>these have <strong>transferrin receptors </strong>(TfRs) in their plasma membrane that bind <strong>transferrin </strong>(Tf) bound to <strong>two iron</strong></p></li><li><p>this triggers <strong>receptor-mediated endocytosis</strong> (using a clathrin coat) into the RBC to form an<strong> early endosome</strong> containing a membrane iron transporter and a proton pump</p></li><li><p><strong>maturation </strong>of the early endosome into the <strong>late </strong>endosome, producing a <strong>more acidic lumen</strong> (influx of H<sup>+</sup>), causes iron to <strong>dissociate </strong>from Tf and be <strong>exported </strong>into the cytosol</p></li><li><p><strong>Tf and TfR are recycled </strong>back to the plasma membrane and extracellular space</p></li><li><p>during reticulocyte <strong>maturation </strong>TfR are <strong>lost </strong>from the PM by <strong>internalisation </strong>into <strong>intraluminal vesicles </strong>and <strong>export </strong>as part of <strong>EVs</strong>, once the desired iron levels are achieved (30 minutes)</p></li></ul><p></p>
13
New cards

how are extracellular vesicles involved in reproductive physiology?

  • EVs are involved in sperm + egg development, implantation and maternal signalling, but we will focus on sperm motility and fertilisation

  • prostasomes (exosomes/small EVs) are released from the prostate gland into the seminal fluid

  • these increase sperm motility because they transfer a calcium uptake toolkit, increasing the intracellular calcium concentration and causing hyperactivation

  • this also increases the ability of sperm to fertilise the egg


<ul><li><p>EVs are involved in sperm + egg development, implantation and maternal signalling, but we will focus on <strong>sperm motility and fertilisation</strong></p></li><li><p><strong>prostasomes </strong>(exosomes/small EVs) are released from the <strong>prostate </strong>gland into the <strong>seminal fluid</strong></p></li><li><p>these<strong> increase sperm motility </strong>because they transfer a <strong>calcium uptake</strong> toolkit, <strong>increasing </strong>the intracellular calcium concentration and causing <strong>hyperactivation</strong></p></li><li><p>this also increases the ability of sperm to <strong>fertilise </strong>the egg</p></li></ul><p></p>
14
New cards

how are extracellular vesicles involved in pathology and the immune response?

  • in certain COVID-19 patients, the EVs express an initiator of blood coagulation as a surface marker

  • these have biological activity as a clotting agent in the infection

  • this can also be used as a diagnostic marker for COVID-19 prognosis


  • EVs are also released by white blood cells to cause an immune response in T cells

  • this was the first experimental evidence for the biological function/activity of EVs → use in therapeutics


<ul><li><p>in certain <strong>COVID-19</strong> patients, the EVs express an <strong>initiator of blood coagulation</strong> as a surface marker</p></li><li><p>these have biological activity as a <strong>clotting agent </strong>in the infection</p></li><li><p>this can also be used as a <strong>diagnostic marker</strong> for COVID-19 prognosis</p></li></ul><p></p><ul><li><p>EVs are also released by<strong> white blood cells </strong>to cause an <strong>immune response </strong>in <strong>T cells</strong></p></li><li><p>this was the first experimental evidence for the biological function/activity of EVs → use in therapeutics</p></li></ul><p></p>
15
New cards

what are some examples of how extracellular vesicles are involved in non-mammalian systems?

a lot of skepticism initially because many didn’t believe EVs could permeate a fungal or plant cell wall


  • fungal EVs coordinate biofilm formation, fungal cell adhesion + antifungal drug resistance


  • EVs are specifically regulated + induced in the plant immune response- intercellularly, to transport defence-related proteins, and in plant-pathogen interactions, containing siRNAs to suppress virulence

  • at the same time, the pathogen produces EVs to suppress immunity in the plant host, in a continual arms race to suppress each other’s phenotypic immune responses


<p>a lot of <strong>skepticism</strong> initially because many didn’t believe EVs could permeate a fungal or plant cell wall</p><p></p><ul><li><p>fungal EVs coordinate <strong>biofilm </strong>formation, fungal cell adhesion + antifungal drug resistance</p></li></ul><p></p><ul><li><p>EVs are specifically regulated + induced in the<strong> plant immune response- </strong>intercellularly, to transport <strong>defence-related proteins</strong>, and in plant-pathogen <strong>interactions</strong>, containing siRNAs to <strong>suppress virulence</strong></p></li><li><p>at the same time, the <strong>pathogen </strong>produces EVs to <strong>suppress immunity</strong> in the plant host, in a continual arms race to suppress each other’s phenotypic immune responses</p></li></ul><p></p>
16
New cards

why can extracellular vesicles be used in therapeutics and diagnostics?

  • EVS are able to modulate the function of recipient cells, causing phenotypic changes → eg. released by white blood cells to induce an immune response in T cells

  • EVs can be used as diagnostic markers because the cargo they contain is specific and characteristic of the donor, eg. for tumour cells (since tumour-specific mRNA variants and miRNAs in EVs released by glioblastomas can be detected in serum), eg. for COVID-19 (blood clotting factor surface marker on EVs of infected patients)

  • Evs can be transported across large distances, so they are ideal candidates for vectors, eg in gene therapy for specific nucleic acid delivery

  • EVs produced by the patient’s cells are non-immunogenic


<ul><li><p>EVS are able to modulate the function of <strong>recipient </strong>cells, causing <strong>phenotypic changes </strong>→ eg. released by white blood cells to induce an <strong>immune response</strong> in T cells</p></li><li><p>EVs can be used as <strong>diagnostic markers</strong> because the cargo they contain is specific and <strong>characteristic </strong>of the donor, eg. for <strong>tumour </strong>cells (since tumour-specific mRNA variants and miRNAs in EVs released by <strong>glioblastomas </strong>can be detected in serum), eg. for <strong>COVID-19</strong> (blood <strong>clotting </strong>factor surface marker on EVs of infected patients)</p></li><li><p>Evs can be transported across <strong>large distances,</strong> so they are ideal candidates for <strong>vectors</strong>, eg in gene therapy for specific nucleic acid delivery</p></li><li><p>EVs produced by the patient’s cells are <strong>non-immunogenic</strong></p></li></ul><p></p>